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Abstract  
Background and aims: Increased concentrations of calculated remnant cholesterol in 
triglyceride-rich lipoproteins are observationally and genetically, causally associated with 
increased risk of ischemic heart disease; however, when measured directly the fraction of 
plasma cholesterol present in remnant particles is unclear. We tested the hypothesis that a 
major fraction of plasma cholesterol is present in remnant lipoproteins in individuals in the 
general population. 
Methods: We examined 9,293 individuals from the Copenhagen General Population Study 
using nuclear magnetic resonance spectroscopy measurements of total cholesterol, free- and 
esterified cholesterol, triglycerides, phospholipids, and particle concentration. Fourteen 
subclasses of decreasing size and their lipid constituents were analysed: six subclasses were 
very low-density lipoprotein(VLDL), one intermediate-density lipoprotein(IDL), three low-
density lipoprotein(LDL), and four subclasses were high-density lipoprotein(HDL). Remnant 
lipoproteins were VLDL and IDL combined. 
Results: Mean nonfasting cholesterol concentration was 1.84mmol/L(72mg/dL) for remnants, 
2.01mmol/L(78mg/dL) for LDL, and 1.83mmol/L(71mg/dL) for HDL, equivalent to remnants 
containing 32% of plasma total cholesterol. Of 14 lipoprotein subclasses, large LDL and IDL 
were the ones containing most of plasma cholesterol. The plasma concentration of remnant 
cholesterol was from ~1.4mmol/L(54mg/dL) at age 20 to ~1.9mmol/L(74mg/dL) at age 60. 
Corresponding values for LDL cholesterol were from ~1.5mmol/L(58mg/dL) to 
2.1~mmol/L(81mg/dL). 
Conclusion: Using direct measurements, one third of total cholesterol in plasma was present 




The leading cause of lost healthy life years globally is cardiovascular disease (1, 2). This is 
mainly due to ischemic heart disease and stroke (1), and yearly 18 million individuals die 
from cardiovascular disease worldwide (2). Important metabolic changes associated with 
cardiovascular disease are hypertension, obesity, diabetes mellitus, and hyperlipidemia (3). 
For the latter, clinical practice has focused on lowering low-density lipoprotein (LDL) 
cholesterol, based on strong evidence that use of lipid-lowering statins lowers both LDL 
cholesterol and the risk of atherosclerotic cardiovascular disease (4, 5). Nevertheless, a 
considerable residual risk remains after achieving recommended LDL cholesterol targets (6, 
7). Such residual risk could partly be explained by cholesterol in the triglyceride-rich 
lipoproteins (4, 5). 
Human and animal studies have shown that the triglyceride-rich lipoproteins 
chylomicron remnants, very low-density lipoproteins (VLDL), and intermediate-density 
lipoproteins (IDL) like LDL can enter the arterial intima and become trapped (5, 8, 9); 
however, large chylomicrons and the largest VLDL particles cannot enter the arterial intima 
because of their size (10-12). Resistance from the blood pressure gradient from the arterial 
lumen across the arterial wall to no pressure in the adventitia combined with attachment to 
proteoglycans and other components of the arterial intima leads to LDL entrapment, causing 
accumulation of cholesterol and subsequently atherosclerosis (5). Triglyceride-rich 
lipoproteins likely are trapped in the arterial intima by similar mechanisms; however, and 
because of their larger size, returning to the arterial lumen could be more difficult than for 
LDL (4, 5).  
Lipoproteins contain different concentrations of cholesterol esters, free 
cholesterol, triglycerides, phospholipids, and various proteins (13). The atherogenic part of 
triglyceride-rich lipoproteins is most likely the cholesterol content, also known as remnant 
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cholesterol, while plasma triglycerides are a marker of the amount of remnant cholesterol 
because of the correlation between these two lipid components of the same particles (4). 
Nuclear magnetic resonance (NMR) spectroscopy offers the opportunity of 
detailed measurements of how cholesterol is distributed in different lipoprotein subclasses. 
The classification of lipoproteins has traditionally been based on density and size determined 
by ultracentrifugation and gel filtration, ranging from the largest chylomicrons and VLDL to 
the smaller IDL, LDL, and HDL (14). Exploring how cholesterol is distributed in a detailed 
continuum of the lipoprotein fractions in individuals in the general population may contribute 
to the understanding of how atherosclerosis develops.  
Here, we used detailed lipoprotein subclass profiles, measured by NMR 
spectroscopy, from 9,293 individuals from the Copenhagen General Population Study to test 
the hypothesis that a major fraction of total cholesterol in plasma drawn nonfasting is present 
in lipoproteins larger than LDL, that is, in IDL, VLDL, and chylomicron remnants. As all 
chylomicrons secreted from the intestine and all VLDLs secreted by the liver have some 
triglycerides hydrolysed immediately after entrance into the bloodstream, all triglyceride-rich 
lipoproteins can be considered as remnants (4, 5, 14). To simplify the nomenclature, we 
therefore use the term remnant cholesterol corresponding to cholesterol in all triglyceride-rich 
lipoproteins combined (IDL+VLDL+chylomicron remnants). The reference method for LDL 
cholesterol measurement combines ultracentrifugation to remove VLDL and chylomicrons 
including their remnants and heparin-Mn2+ precipitation to separate LDL particles from HDL 
(15). With this method, the lipoprotein fraction in the density range of 1.006-1.063 g/ml is 
defined as LDL, and the fraction in the density range of 1.063-1.21 g/ml is defined as HDL. 
However, it is not widely recognized that the LDL cholesterol fraction on the reference 
method using ultracentrifugation also contains the cholesterol from IDL with density 1.006-
1.019 g/ml (15) (see Table 1 in Nordestgaard BG (13)). 
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Materials and methods  
The Copenhagen General Population Study 
The Copenhagen General Population Study is an ongoing cohort study initiated in 2003. In 
the present study, we included individuals recruited in 2003-2004 (response rate 49%). 
Individuals of Danish descent (Danish citizens born in Denmark with parents also being 
Danish citizens born in Denmark) aged 20 or above were randomly invited, using the Danish 
Central Person Register, to reflect the adult white Danish population. Individuals filled in a 
questionnaire, underwent a physical examination, and had blood samples drawn.  
Present study was conducted according to the Declaration of Helsinki. Written 
informed consent was obtained from all individuals and the study was approved by the Ethics 
Committee of the Capital Region of Denmark (H-KF-01-144/01) and by the Danish Data 
Protection Agency.  
 
Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy was used to quantify detailed nonfasting lipoprotein measurements by the 
Metabolomic Core Facility at the University of Bristol operating on Nightingale Health´s 
platform, a widely used platform in epidemiological studies that has been described 
previously (16-18). Multiple plasma biomarkers are characterised by the protons in the 
biomarkers hydrogen atoms using a strong magnetic field exposed to electromagnetic 
radiation, are analysed by their resonance frequencies giving rise to a NMR spectrum, and 
thereby concentrations of the biomarkers in the plasma are measured (16, 17). Over 200 
metabolic biomarkers were quantified in the categories cholesterol, fatty acids, glycerides, 
phospholipids, apolipoproteins, amino acids, glycolysis related metabolites, ketone bodies, 
fluid balance, inflammation, lipoprotein particle size, and lipoprotein subclasses (16-18). The 
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14 lipoprotein subclasses measured included XXL VLDL, XL VLDL, L VLDL, M VLDL, S 
VLDL, XS VLDL, IDL, L LDL, M LDL, S LDL, XL HDL, L HDL, M HDL, and S HDL 
(16-18) (Supplementary Figure 1). For each lipoprotein subclass, total cholesterol, free 
cholesterol, esterified cholesterol, triglycerides, phospholipids, particle concentration, and 
ratios of lipid contents in particles are measured (16-18). Furthermore, the mean particle sizes 
for VLDL, LDL (including IDL), and HDL are calculated (16-18).  It is not possible to 
differentiate between chylomicrons and VLDL and their remnants by NMR spectroscopy, and 
chylomicrons and their remnants are therefore part of the VLDL fractions; intact 
chylomicrons are in the XXL VLDL fraction, while chylomicrons remnant can be in any 
VLDL subfraction or even in IDL, depending on their size. 
 Data on the analytical performance and technical variance of Nightingale’s 
nuclear magnetic resonance spectroscopy platform on other cohorts has been published (19, 
20). In short, coefficients of variations (CVs) for the NMR-based metabolic measures have 
previously been found to be 2.1% for total cholesterol, 2.3% for LDL cholesterol, 2.3% for 
HDL cholesterol, and 1.2% for total triglycerides (19). CVs for other metabolic measures are 
typically below 5% (19). 
 
Biochemical analyses 
Standard hospital assays were used to measure nonfasting (21) total cholesterol, HDL 
cholesterol and triglycerides on fresh samples (Konelab, Helsinki, Finland). LDL cholesterol 
was calculated using the Friedewald equation when triglycerides were <4mmol/L 
(354mg/dL), and otherwise measured directly (Konelab). In the original Friedewald equation, 
the triglyceride cutpoint of 400mg/dL (4.5mmol/L) was used (22); however, for simplicity we 
adapted the 4mmol/L (354mg/dL) cutpoint as mmol/L is the unit used in Denmark. 
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Baseline values  
Alcohol intake was self-reported drinks per week (1 drink ≈12g alcohol). Physical activity in 
leisure time was dichotomized as being physically inactive (doing no or light physical activity 
in leisure time <4 hours/week) and being physically active (>4 hours/week of light physical 
activity or ≥2 hours/week of vigorous physical activity in leisure time). Height and weight 
were measured at baseline, and body mass index calculated as weight (kg) divided by height 
squared (m2). Systolic blood pressure was measured at baseline (mmHg). Diabetes mellitus 
was nonfasting glucose >11mmol/L (198mg/dL), self-reported diabetes mellitus, use of 
antidiabetic medication, and/or a diabetes mellitus diagnosis from the national Danish Patient 
Registry (ICD-8: 250; ICD-10: E10, E11, E13, E14). 
 
Statistical analyses 
Stata/SE 13 was used. As is standard with respect to ultracentrifugation, cholesterol and 
triglycerides in the different lipoprotein fractions measured by NMR spectroscopy were 
corrected, separately for each individual person, for recovery relative to total plasma 
cholesterol and triglycerides measured on fresh samples at the day of attendance 
(Supplementary Figure 2). Since we had no measurement of total phospholipids on fresh 
samples, the recovery for phospholipids was defined as the average of the recovery for total 
cholesterol and triglycerides in each individual separately. The largest VLDL was calculated 
by adding XXL VLDL, XL VLDL, and L VLDL while the smallest VLDL was calculated by 
adding M VLDL, S VLDL and XS VLDL. Remnant cholesterol was defined as cholesterol in 
IDL+VLDL including chylomicron remnants.  
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The particle size ranges were approximated as the median value between the 
average size for each particle subclass (see Figure 2 in Pasi Soininen et al. (17)). For XXL 
VLDL and S HDL the particle sizes were given as more than the median between XXL 
VLDL and XL VLDL and for S HDL the particle sizes were given as less than the median 
between M HDL and S HDL (17).  
The particle concentrations given in mol/L were converted to particles/L by 
multiplying with Avogadro’s constant (6.02214076×1023 particles/mol). Kernel density 
estimation was used to estimate distribution of mean particle diameters and particle 
concentrations, whereas kernel-weighted local polynomial smoothing curves, with 95% 
confidence intervals, were used to study LDL and remnant cholesterol concentrations by age.  
For VLDL, LDL+IDL (IDL was included in the measurement of mean particle 
diameter of LDL) and HDL the mean sizes were calculated by weighting the subclass 
diameters with their particle concentrations (See supplementary Table 1 Krista Fischer et al 
(23)). For IDL there is only one subclass with an average particle diameter defined as 28.6nm 
(17, 23) and therefore the mean particle diameter of IDL alone is drawn as an assumption 
with a mean of 28.6nm. 
R2 was taken from linear regression models between LDL- and IDL-, VLDL-, 








Supplementary Table 1 shows baseline characteristics of 9,293 individuals from the 
Copenhagen General Population Study recruited in 2003-2004 using standard hospital assays. 
Mean plasma concentrations were 5.7mmol/L (220mg/dL) for total cholesterol, 3.3mmol/L 
(127mg/dL) for “LDL” cholesterol including LDL+IDL, and 1.8mmol/L (161mg/dL) for total 
triglycerides. 
 
Lipoprotein sizes and particle numbers  
The mean particle diameter of the lipoproteins in each individual in the Copenhagen General 
Population Study was 37.1nm (range: 33.1nm–41.9nm) for VLDL, 23.6nm (23.2nm–24.5nm) 
for LDL (including IDL), and 10.0nm (9.3nm–11.1nm) for HDL (Figure 1). For comparison 
to the other lipoproteins, an approximation of the mean particle diameter for IDL at 28.6nm 
(28.4nm-28.8nm) was added to Figure 1. The mean particle diameters of the lipoproteins were 
approximately normally distributed.  
Distributions of concentrations in particles/L in all 14 lipoprotein subclasses are 
shown in Figure 2. Overall the particle number per liter increased with increasing density of 
the lipoprotein and thus with decreasing size. Mean particles/L were 1.1 x 1014 for XXL 
VLDL, 5.7 x 1014 for XL VLDL, 3.5 x 1015 for L VLDL, 1.2x 1016 for M VLDL, 1.8x 1016 for 
S VLDL,  2.3 x 1016 for XS VLDL, 6.4 x 1016 for IDL,  1.0 x 1017 for L LDL, 8.2 x 1016 for M 
LDL, 9.5 x 1016 for S LDL, 2.7 x 1017 for XL HDL, 7.3 x 1017 for L HDL, 1.2 x 1018 for M 
HDL, and 2.8x 1018 for S HDL.  
 
Lipoprotein particle composition 
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Mean fractions of cholesterol, including both cholesterol esters and free cholesterol, were 
18% for XXL VLDL, 22% for XL VLDL, 24% for L VLDL, 28% for M VLDL, 35% for S 
VLDL, 46% for XS VLDL, 62% for IDL, 66% for L LDL, 64% for M LDL, 60% for S LDL, 
48% for XL HDL, 47% for L HDL, 47% for M HDL, and 39% for S HDL (Figure 3, bottom 
section). Corresponding triglyceride mean fractions were 70%, 61%, 58%, 51%, 41%, 23%, 
11%, 9%, 7%, 7%, 5%, 4%, 6%, and 5%, respectively, while corresponding phospholipid 
mean fractions were 11%, 16%, 18%, 20%, 24%, 30%, 27%, 25%, 28%, 32%, 47%, 49%, 
47%, and 56%, respectively.  
The lipoprotein subclasses containing most of the plasma cholesterol were L 
LDL with a median cholesterol ester concentration of 0.75mmol/L (29mg/dL) and a median 
free cholesterol concentration of 0.30mmol/L (12mg/dL), followed by IDL with a median 
cholesterol ester concentration of 0.62mmol/L (24mg/dL) and a median free cholesterol 
concentration of 0.24mmol/L (9mg/dL) (Figure 3, top section). The lipoprotein subclass 
containing most of the triglycerides was M VLDL with a median triglyceride concentration of 
0.34mmol/L (30mg/dL) followed by S VLDL with a median triglyceride concentration of 
0.26mmol/L (23mg/dL). The lipoprotein subclass contributing most to the plasma 
phospholipid concentration was S HDL with a median concentration of 0.70mmol/L 
(27mg/dL). 
 
Remnant cholesterol and LDL cholesterol  
Higher concentrations of LDL cholesterol were associated with higher concentrations of 
remnant cholesterol, VLDL cholesterol, and IDL cholesterol (Supplementary Figure 3). As 
LDL cholesterol increased, VLDL cholesterol increased with a correlation coefficient of 0.34 
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and an R2 of 0.23, IDL cholesterol with a correlation coefficient of 0.37 and an R2 of 0.94, and 
remnant cholesterol with a correlation coefficient of 0.71 and an R2 of 0.52.  
The plasma concentration of remnant cholesterol and LDL cholesterol was 
lowest for individuals at age 20, highest for individuals at age 60 and thereafter slightly lower 
(Figure 4). The plasma concentration of remnant cholesterol was ~1.4mmol/L (54mg/dL) at 
age 20 and ~1.9mmol/L (74mg/dL) at age 60. Corresponding values for LDL cholesterol were 
~1.5mmol/L (58mg/dL) and ~2.1mmol/L (81mg/dL). 
 
Cholesterol and triglycerides in different lipoprotein fractions 
For plasma total cholesterol (=free cholesterol + esterified cholesterol) the distribution was 
32% in remnant lipoprotein particles (largest VLDL, smallest VLDL, and IDL combined), 
35% in LDL particles, and 32% in HDL particles (Table 1). The mean cholesterol 
concentration was 1.84mmol/L (72mg/dL) for remnant lipoproteins, 2.01mmol/L (78mg/dL) 
for LDL, and 1.83mmol/L (71mg/dL) for HDL. For plasma total triglycerides the distribution 
was 77% in remnant lipoprotein particles, 13% in the LDL particles, and 11% in the HDL 
particles (Table 1). For triglycerides the mean concentration was 1.39mmol/L (124mg/dL) for 








In this cohort study of 9,293 individuals from the Copenhagen General Population Study 
using direct measurements, we found that one third of total cholesterol in plasma was present 
in remnant lipoproteins, which is a fraction corresponding to the cholesterol content in LDL. 
These findings add new knowledge to the understanding of the cholesterol distribution in 
different lipoprotein subfractions and may help refocus attention in cardiovascular prevention 
toward other lipoproteins than LDL alone. 
Remnant lipoproteins enter the arterial intima, though at a slightly slower speed 
than LDL particles; however, due to their large size remnant lipoproteins seems to get trapped 
in the intima preferentially to LDL particles by attachment to components such as 
proteoglycans, and by the constant lumen to intima fluid flow due to blood pressure in the 
lumen (4, 5, 8, 9, 12, 24). In the intima remnants are taken up directly by macrophages 
without need for modification and thereby macrophages become foam cells that develop into 
atherosclerotic plaques; this is unlike for LDL that needs to be modified before uptake into 
macrophages (4, 5, 25). Furthermore, hydrolysis of triglycerides in remnant lipoproteins may 
generate local inflammation in the arterial wall and through this contribute to atherogenesis 
with vulnerable plaques (4, 5, 26). Besides cholesterol and triglyceride content, particle 
number per se may also be important (27). For individuals with similar concentrations of 
VLDL cholesterol, IDL cholesterol and LDL cholesterol, the lipoprotein particle number can 
vary, and individuals with the largest number of VLDL, IDL and/or LDL particles might be at 
higher risk of developing cardiovascular disease (7, 28, 29). 
In a prospective study of 106,216 individuals from the Copenhagen General 
Population Study, where 1,565 individuals had a myocardial infarction, stepwise higher 
calculated remnant cholesterol was associated with stepwise higher risk of myocardial 
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infarction across the examined body mass index subcategories, suggesting that remnant 
cholesterol is a risk factor for myocardial infarction independent of overweight and obesity 
(30). Furthermore, a recent study reported that individuals with high calculated remnant 
cholesterol concentrations had higher risk of ischemic stroke (31). Given such data it seems 
valuable simply to calculate remnant cholesterol, and that reduction of remnant cholesterol no 
matter how low (except for <0.5mmol/L (19mg/dL)) or high may benefit to reduce 
cardiovascular disease; however, this needs to be tested in randomized trials. 
A previous study suggests that increased concentrations of both calculated and 
directly measured remnant cholesterol with an assay by Denka Seiken were associated with 
increased all-cause mortality in patients with ischemic heart disease (32). It could be 
speculated that calculated remnant cholesterol and remnant cholesterol measured with nuclear 
magnetic resonance spectroscopy provide similar credibility of all-cause mortality risk, and 
maybe also risk of cardiovascular disease. If this were the case, calculated remnant cholesterol 
is most easily accessible and therefore could be preferred in the clinic; however, nuclear 
magnetic resonance spectroscopy can be used to examine the cholesterol distribution in 
lipoproteins in detail. 
There are different ways of determining the concentration of remnant 
cholesterol, including calculating it from a standard lipid profile and measuring it directly by 
ultracentrifugation, direct remnant cholesterol assays, and as in the present study by NMR 
spectroscopy (5, 14, 30, 33, 34). A Chinese population based study, also using the Nightingale 
Health´s platform as in the present study, found similar fractions of cholesterol in remnants in 
nonfasting samples as in the present study (20). 
Debate over lipoprotein fractions has been ongoing for decades. Early studies 
used density cuts, but density gradient, and other methods, have demonstrated that 
lipoproteins are better characterised by a continuous function, i.e. that fractions are not 
 14 
discrete populations, but rather a collection of particles that overlap in biochemical and 
metabolic properties. However, in clinical practice density cuts for LDL cholesterol and HDL 
cholesterol are used throughout, making the present data relevant for evaluation of lipids and 
lipoproteins in clinical practice. 
A study of 4756 white men and women recruited in 1971-1976 used 
ultracentrifugation to measure cholesterol in VLDL, LDL (including IDL) and HDL, and 
found mean VLDL cholesterol concentrations that were about half of the VLDL cholesterol 
concentrations in present study and LDL cholesterol concentrations that were ~1,5 times 
higher than in present study (35); however, that study excluded individuals older than 59 
years and recruited in a time-period with much less obesity than today, which together with 
using a different method, could explain the different results compared to our study. 
Furthermore, that study did not estimate IDL cholesterol separately, and IDL cholesterol was 
therefore included in LDL cholesterol.  
In previous studies estimating remnant cholesterol by calculation from a 
standard lipid profile (measured by standard hospital assays), concentrations were lower than 
in the present study using NMR spectroscopy (30, 36, 37). Also, LDL cholesterol 
concentrations were higher since IDL cholesterol was included in LDL cholesterol. In present 
study, mean LDL cholesterol measured using a standard hospital assay was 3.3mmol/L, while 
LDL cholesterol and IDL cholesterol measured with nuclear magnetic resonance spectroscopy 
added together were 2.0mmol/L+0.9mmol/L=2.9mmol/L.  
Furthermore, previously used direct remnant assays only measures cholesterol in 
a subset of chylomicron remnants and VLDLs, and in a previous study we found that one of 
these assays only quantified around 13% of the concentration of calculated remnant 
cholesterol (5, 30, 34). There has recently been developed a direct assay that measures the 
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cholesterol content of all remnants (all triglyceride-rich lipoproteins), with concentrations 
comparable to calculated remnant cholesterol (30). 
Other advanced lipoprotein profiling methods are difficult to compare with 
NMR spectroscopy, since the nomenclature is not uniform among the methods and the 
number of lipoprotein particles also differ (29). Additionally, to our knowledge no large-scale 
study has focused on the amount of cholesterol in triglyceride-rich lipoproteins using these 
methods, and the present study gives the most detailed quantitative description of remnant 
cholesterol so far.   
In the present study, directly measured remnant cholesterol was higher for 
individuals aged 60 compared to individuals aged 20. Previous ultracentrifugation studies 
recruiting participants in the 1970s to the 1990s have suggested that LDL cholesterol was 
higher in older individuals for both sexes, whereas VLDL cholesterol also was higher in 
individuals with a higher age for women and men, but only until the age of around 50 years 
for men (35, 38). Other NMR spectroscopy studies also show a possible association between 
aging and metabolomic changes, including subclasses of lipoprotein cholesterol (39-41).  
Strengths of the present study include the large sample size representing the 
adult white Danish general population. Furthermore, the Nightingale Health platform offers a 
direct measurement of the cholesterol, triglyceride, and phospholipid distribution in 14 
lipoprotein subfractions, allowing for a detailed and precise estimation of remnant cholesterol.  
Some limitations should be mentioned. In present study using the nuclear magnetic resonance 
platform there are scaling issues compared with established biochemical laboratory 
measurements that need to be clarified. The measurements of plasma total cholesterol and 
triglycerides were slightly lower using NMR spectroscopy compared to using standard 
hospital biochemical assays; however, this is a previously known limitation not only applying 
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to our study (20, 29, 42). To account for this, cholesterol and triglycerides in the different 
lipoprotein fractions were corrected for recovery relative to total plasma cholesterol and 
triglycerides measured by standardized hospital biochemical assays on fresh samples 
collected at the day of attendance for each person. The standardized hospital biochemical 
assays are traceable to WHO standard calibrators and monthly checked for accuracy. 
Correction for recovery is a known method commonly used in ultracentrifugation, and the 
mean average recoveries of 88% for triglycerides and of 76% for cholesterol in the present 
NMR spectroscopy are corresponding to the mean average recoveries in ultracentrifugation 
(43, 44); that said, differences in calibrations from measurement of triglycerides and 
cholesterol between standard hospital assays and NMR spectroscopy may also lead to some 
measurement differences between the two methods. Also, long-term storage might give rise to 
subtle degradation of lipoproteins even though the samples were kept at -80C (29), and this 
could also explain some of the difference in concentrations between NMR spectroscopy and 
standard hospital assays in our study. Furthermore, it is a limitation that it is not possible to 
differentiate between chylomicrons and their remnants and VLDL and their remnants using 
the NMR spectroscopy method. 
  Another limitation is that the present study included white individuals of Danish 
descent only and therefore the distribution of the lipoprotein subclasses, lipid content, sizes, 
and particle numbers may not necessarily be generalisable to other ethnicities; however, we 
are not aware of any data suggesting that the present results should not apply to other 
populations in affluent countries with similar fractions of overweight and obese individuals in 
the general population. 
It could be argued that the term “remnant cholesterol” covering cholesterol in all 
triglyceride-rich lipoproteins is too simplified and that we instead should have used the term 
“triglyceride-rich lipoprotein cholesterol”. There is no common definition of remnant 
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cholesterol, and some experts think that remnant cholesterol intuitively should only comprise 
lipoprotein particles arising from the chain of delipidation of triglyceride-rich lipoproteins 
that in some way or another are stuck or are no longer following through the expected 
conversion to particles that have a defined and efficient removal mechanism. It could also be 
argued that, the proportion of the triglyceride-rich lipoproteins that are in a sequence of 
successful delipidation destined for a final state of receptor-mediated uptake, or some rapidly 
removed delipidated chylomicron remnants should not be defined as remnant lipoproteins. 
However, as soon as chylomicrons from the intestine or VLDL from the liver enter the 
bloodstream, lipoprotein lipase will immediately start degrading some of the triglycerides in 
these particles. Therefore, essentially all triglyceride-rich lipoproteins in plasma, except for 
the rare case of complete lipoprotein lipase deficiency, can be considered some form of a 
remnant. We therefore prefer to use the simplified “remnant cholesterol” as this for most 
clinicians will be easier to understand than the term triglyceride-rich lipoprotein cholesterol.  
In conclusion, in this study of 9,293 individuals from the general population 
using direct measurement, we found that one third of total cholesterol in plasma was present 
in remnant lipoproteins, that is, in the triglyceride-rich lipoproteins IDL+VLDL+ chylomicron 
remnants. Randomized controlled trials are needed to examine if lowering remnant 
cholesterol will reduce the risk of cardiovascular disease. 
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Figure 1.  Distribution of mean particle diameter in 9,293 individuals in the Copenhagen 
General Population Study.  
For VLDL, LDL+IDL (IDL was included in the measurement of mean particle diameter of 
LDL) and HDL the mean sizes were calculated by weighting the subclass diameters with their 
particle concentrations. For IDL there is only one subclass with an average particle diameter 
defined as 28.6nm and therefore the mean particle diameter of IDL alone is drawn as an 
assumption with a mean on 28.6nm. HDL: high-density lipoprotein. IDL: intermediate-
density lipoprotein. LDL: low-density lipoprotein. VLDL: very low-density lipoprotein. 
Figure 2. Distribution of particle numbers in 9,293 individuals in the Copenhagen 
General Population Study. 
 Number and size of lipoprotein particles were measured by nuclear magnetic resonance 
spectroscopy. Note that the scale for the x-axis for HDL particles is approximately 20-fold 
that for the x-axes used for LDL, IDL, and VLDL particles. HDL: high-density lipoprotein. 
IDL: intermediate-density lipoprotein. LDL: low-density lipoprotein. VLDL: very low-
density lipoprotein. X: extra. 
Figure 3. Lipoproteins sizes and contents in 9,293 individuals in the Copenhagen 
General Population Study.  
Cholesterol, triglycerides, and phospholipids in the different lipoprotein fractions were 
measured by nuclear magnetic resonance spectroscopy, and corrected for recovery as 
described in Methods. Phospholipids are only given in mmol/L only as unit conversion to 
mg/dL cannot be done unambiguously. HDL: high-density lipoprotein. IDL: intermediate-
density lipoprotein. L: large. LDL: low-density lipoprotein. M: medium. S: small. VLDL: 
very low-density lipoprotein. XL: extra large. XS: extra small. XXL: extra extra large. 
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Figure 4. Cholesterol concentrations at different age groups in 9,293 individuals in the 
Copenhagen General Population Study.  
The figure shows kernel-weighted local polynomial smoothing curves. Remnant 
cholesterol=intermediate-density lipoprotein cholesterol + very low-density lipoprotein 
cholesterol(including chylomicron remnants). LDL: low-density lipoprotein. 
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Table 1. Cholesterol and triglyceride content by lipoprotein size in individuals in the Copenhagen General Population Study 
   
Mean free + esterified 
cholesterol 
Mean triglycerides 
Lipoprotein Subclassification Size,nm mmol/L mg/dL % mmol/L mg/dL % 
Remnant lipoproteins       VLDL + IDL ≥27.2 1.84 72 32% 1.39 124 77% 
        Largest VLDL XXL + XL + L ≥49.2 0.14 6 3% 0.36 32 20% 
        Smallest VLDL M + S + XS 30.1-49.1 0.82 32 14% 0.89 79 49% 
        IDL 
 
27.2-30 0.88 34 15% 0.14 13 8% 
LDL L+ M+ S 16.6-27.1 2.01 78 35% 0.23 20 13% 
HDL XL + L + M + S ≤16.5 1.83 71 32% 0.19 17 11% 
Total 
  
5.67 221 100% 1.81 161 100% 
Cholesterol and triglycerides in the different lipoprotein fractions were measured by nuclear magnetic resonance spectroscopy followed by 
correction for recovery relative to values from standard hospital assays using fresh samples, as described in the Methods. Because of rounding of 
numbers, the ratio between mmol/L and mg/dL vary slightly. HDL: high-density lipoprotein. IDL: intermediate-density lipoprotein. L: large. 
LDL: low-density lipoprotein. M: medium. S: small. VLDL: very low-density lipoprotein. XL: extra large. XS: extra small. XXL: extra extra 
large. 
